Physician profile
Angela E Macdonald
NPI 1952405417
$2,437.25
in general payments reported to CMS, 2019-2025
12 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2021: $101 · 2022: $371 · 2023: $520 · 2024: $991 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $648.31 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $328.24 | 2023-2024 | Infuse, Biotrue, Xiidra |
| Alcon Vision LLC | $264.57 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Sun Pharmaceutical Industries INC. | $257.02 | 2022-2024 | Cequa |
| Biotissue Holdings INC. | $231.84 | 2024 | |
| Abbvie INC. | $150.72 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $147.04 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $135.46 | 2021-2023 | Acuvue |
| Astellas Pharma US INC | $118.77 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $70.00 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $49.93 | 2025 | Xdemvy |
| Allergan, INC. | $35.35 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.